Third generation cephalosporins.
The third generation cephalosporins demonstrate greater potency, broader antibacterial spectrum, and more favorable pharmacologic characteristics than other cephalosporins. The majority of strains of E. coli, Klebsiella pneumoniae, and Proteus are susceptible, including strains resistant to aminoglycosides, anti-Pseudomonas penicillins, and other cephalosporins. Pseudomonas aeruginosa is susceptible to a subgroup of third generation agents including ceftazidime, cefoperazone, and the experimental agents cefpirome and cefpiramide. Penetration into the cerebrospinal fluid is excellent especially for cefotaxime, ceftazidime, ceftriaxone, and ceftizoxime. These agents are safe, sharing most of the known toxicities of other beta-lactam compounds. Their greatest use is in the therapy of difficult to treat gram-negative bacterial infections, including meningitis, nosocomial infections, and infections caused by Pseudomonas aeruginosa.
Donowitz
G R
GR
Department of Internal Medicine, University of Virginia School of Medicine, Charlottesville.
D001419:Bacteria / Q000187:drug effects; D002511:Cephalosporins / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D003428:Cross Infection / Q000188:drug therapy; D006801:Humans; D008581:Meningitis / Q000188:drug therapy; D011552:Pseudomonas Infections / Q000188:drug therapy; D013329:Structure-Activity Relationship
D002511:Cephalosporins